Promis Neurosciences Stock Analysis

PMN Stock  USD 0.82  0.30  26.79%   
ProMIS Neurosciences is undervalued with Real Value of 2.02 and Target Price of 5.78. The main objective of ProMIS Neurosciences stock analysis is to determine its intrinsic value, which is an estimate of what ProMIS Neurosciences is worth, separate from its market price. There are two main types of ProMIS Neurosciences' stock analysis: fundamental analysis and technical analysis.
The ProMIS Neurosciences stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. ProMIS Neurosciences is usually not traded on Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day. ProMIS Stock trading window is adjusted to America/New York timezone.
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in ProMIS Neurosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.
To learn how to invest in ProMIS Stock, please use our How to Invest in ProMIS Neurosciences guide.

ProMIS Stock Analysis Notes

About 28.0% of the company outstanding shares are owned by corporate insiders. The book value of ProMIS Neurosciences was at this time reported as 0.29. The company had not issued any dividends in recent years. ProMIS Neurosciences had 1:60 split on the 28th of June 2022. ProMIS Neurosciences, Inc. discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimers disease , amyotrophic lateral sclerosis , and multiple system atrophy in Canada. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada. Promis Neurosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 5 people. To find out more about ProMIS Neurosciences contact the company at 416 847 6898 or learn more at https://www.promisneurosciences.com.

ProMIS Neurosciences Investment Alerts

ProMIS Neurosciences is way too risky over 90 days horizon
ProMIS Neurosciences has some characteristics of a very speculative penny stock
ProMIS Neurosciences appears to be risky and price may revert if volatility continues
ProMIS Neurosciences has high likelihood to experience some financial distress in the next 2 years
ProMIS Neurosciences has about 8.95 M in cash with (27.18 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.24, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
ProMIS Neurosciences has a frail financial position based on the latest SEC disclosures
Roughly 28.0% of the company outstanding shares are owned by corporate insiders
Latest headline from gurufocus.com: ProMIS Neurosciences Secures Funding to Enhance Therapeutic Development

ProMIS Neurosciences Upcoming and Recent Events

Earnings reports are used by ProMIS Neurosciences to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period..
13th of March 2024
Upcoming Quarterly Report
View
20th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
13th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

ProMIS Largest EPS Surprises

Earnings surprises can significantly impact ProMIS Neurosciences' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2023-11-14
2023-09-30-0.33-0.190.1442 
2025-05-12
2025-03-31-0.172-0.00730.164795 
2022-11-14
2022-09-30-0.85-1.11-0.2630 
View All Earnings Estimates

ProMIS Stock Institutional Investors

Shares
Fiduciary Trust Co2025-03-31
18.6 K
Heights Capital Management Inc2025-03-31
18.3 K
Scotia Capital Inc2025-03-31
12.1 K
Claret Asset Management Corporation2025-03-31
11.3 K
Royal Bank Of Canada2025-03-31
5.5 K
Bank Of America Corp2025-03-31
1.7 K
Td Waterhouse Canada Inc2025-03-31
133
Abound Wealth Management2025-03-31
1.0
Affinity Asset Advisors, Llc2024-12-31
0.0
Great Point Partners Llc2025-03-31
2.6 M
Armistice Capital, Llc2025-03-31
2.3 M
Note, although ProMIS Neurosciences' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

ProMIS Market Capitalization

The company currently falls under 'Micro-Cap' category with a total capitalization of 26.8 M.

ProMIS Profitablity

Last ReportedProjected for Next Year
Return On Tangible Assets 146.94  154.29 
Return On Capital Employed-1 K-958
Return On Assets 146.94  154.29 
Return On Equity 0.17  0.18 

Management Efficiency

ProMIS Neurosciences has Return on Asset of (1.2439) % which means that on every $100 spent on assets, it lost $1.2439. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.1956) %, meaning that it generated no profit with money invested by stockholders. ProMIS Neurosciences' management efficiency ratios could be used to measure how well ProMIS Neurosciences manages its routine affairs as well as how well it operates its assets and liabilities. At this time, ProMIS Neurosciences' Return On Tangible Assets are very stable compared to the past year. As of the 23rd of July 2025, Return On Assets is likely to grow to 154.29, though Return On Capital Employed is likely to grow to (957.65). At this time, ProMIS Neurosciences' Return On Assets are very stable compared to the past year.
Last ReportedProjected for Next Year
Book Value Per Share 0.64  0.60 
Net Current Asset Value 583.44  518.62 
Tangible Asset Value 638.17  567.26 
Tangible Book Value Per Share 0.64  0.60 
Enterprise Value11.3 M10.7 M
ProMIS Neurosciences has shown resilience through effective management strategies. Our analysis examines how these strategies influence financial outcomes and investor returns which helps in understanding the stock's long-term potential.
Beta
(0.09)
Return On Assets
(1.24)
Return On Equity
(0.20)

Technical Drivers

As of the 23rd of July, ProMIS Neurosciences holds the Semi Deviation of 6.54, coefficient of variation of 1253.44, and Risk Adjusted Performance of 0.0815. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of ProMIS Neurosciences, as well as the relationship between them.

ProMIS Neurosciences Price Movement Analysis

The output start index for this execution was thirty-two with a total number of output elements of twenty-nine. The MESA Adaptive Moving Average indicator adapts to ProMIS Neurosciences price movement based on the rate change of phase as measured by the Hilbert Transform Discriminator.

ProMIS Neurosciences Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific ProMIS Neurosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on ProMIS Neurosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases ProMIS Neurosciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Eugene Williams over a month ago
Acquisition by Eugene Williams of 20000 shares of ProMIS Neurosciences at 0.5 subject to Rule 16b-3
 
Sclar Jeremy M. over two months ago
Disposition of 150000 shares by Sclar Jeremy M. of ProMIS Neurosciences subject to Rule 16b-3
 
Sclar Jeremy M. over three months ago
Acquisition by Sclar Jeremy M. of 150000 shares of ProMIS Neurosciences at 14.0 subject to Rule 16b-3
 
Gavin Malenfant over three months ago
Acquisition by Gavin Malenfant of 2660 shares of ProMIS Neurosciences at 1.88 subject to Rule 16b-3
 
Kirwin Patrick D. over three months ago
Acquisition by Kirwin Patrick D. of 11000 shares of ProMIS Neurosciences at 1.88 subject to Rule 16b-3
 
Altstiel Larry Douglas over three months ago
Disposition of 30833 shares by Altstiel Larry Douglas of ProMIS Neurosciences at 7.2 subject to Rule 16b-3
 
Eugene Williams over three months ago
Disposition of 36988 shares by Eugene Williams of ProMIS Neurosciences at 3.9 subject to Rule 16b-3
 
Cashman Neil over three months ago
Acquisition by Cashman Neil of 15000 shares of ProMIS Neurosciences at 0.973 subject to Rule 16b-3
 
Altstiel Larry Douglas over six months ago
Acquisition by Altstiel Larry Douglas of 175000 shares of ProMIS Neurosciences at 1.0 subject to Rule 16b-3
 
Warma Neil K over six months ago
Acquisition by Warma Neil K of 1144122 shares of ProMIS Neurosciences at 1.15 subject to Rule 16b-3
 
Kirwin Patrick D. over six months ago
Acquisition by Kirwin Patrick D. of 40000 shares of ProMIS Neurosciences at 1.11 subject to Rule 16b-3
 
Shafmaster Madge K. over six months ago
Acquisition by Shafmaster Madge K. of 70000 shares of ProMIS Neurosciences at 1.3004 subject to Rule 16b-3

ProMIS Neurosciences Predictive Daily Indicators

ProMIS Neurosciences intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of ProMIS Neurosciences stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

ProMIS Neurosciences Forecast Models

ProMIS Neurosciences' time-series forecasting models are one of many ProMIS Neurosciences' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary ProMIS Neurosciences' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About ProMIS Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how ProMIS Neurosciences prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling ProMIS shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as ProMIS Neurosciences. By using and applying ProMIS Stock analysis, traders can create a robust methodology for identifying ProMIS entry and exit points for their positions.
Last ReportedProjected for Next Year
Pretax Profit Margin-1.3 K-1.4 K
Operating Profit Margin-1.2 K-1.2 K
Net Loss-1.4 K-1.4 K
Gross Profit Margin(646.17)(678.48)

Current ProMIS Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. ProMIS analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. ProMIS analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
5.78Strong Buy3Odds
ProMIS Neurosciences current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most ProMIS analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand ProMIS stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of ProMIS Neurosciences, talking to its executives and customers, or listening to ProMIS conference calls.
ProMIS Analyst Advice Details

ProMIS Stock Analysis Indicators

ProMIS Neurosciences stock analysis indicators help investors evaluate how ProMIS Neurosciences stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading ProMIS Neurosciences shares will generate the highest return on investment. By understating and applying ProMIS Neurosciences stock analysis, traders can identify ProMIS Neurosciences position entry and exit signals to maximize returns.
Begin Period Cash Flow12.6 M
Common Stock Shares Outstanding26.5 M
Total Stockholder Equity16.5 B
Total Cashflows From Investing Activities-693.00
Cash And Short Term Investments13.3 M
Cash13.3 M
Accounts Payable1.7 M
Net Debt-13.3 M
50 Day M A0.5038
Total Current Liabilities2.2 M
Non Current Assets Total33 M
Non Currrent Assets Other-33 M
Stock Based Compensation825.8 K
When determining whether ProMIS Neurosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ProMIS Neurosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Promis Neurosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Promis Neurosciences Stock:
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in ProMIS Neurosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.
To learn how to invest in ProMIS Stock, please use our How to Invest in ProMIS Neurosciences guide.
You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ProMIS Neurosciences. If investors know ProMIS will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ProMIS Neurosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
0.09
Revenue Per Share
0.001
Return On Assets
(1.24)
Return On Equity
(0.20)
The market value of ProMIS Neurosciences is measured differently than its book value, which is the value of ProMIS that is recorded on the company's balance sheet. Investors also form their own opinion of ProMIS Neurosciences' value that differs from its market value or its book value, called intrinsic value, which is ProMIS Neurosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ProMIS Neurosciences' market value can be influenced by many factors that don't directly affect ProMIS Neurosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ProMIS Neurosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if ProMIS Neurosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ProMIS Neurosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.